By the PharmaTradz BD Team. Published October 2026.
In July, the US President announced on social media that imported generic medicines would face a 100% tariff from August 2028, rising to 200% a year later. The stated aim is to bring generic manufacturing back to the United States. Three months on, there is still no signed order, no published list of products and no stated legal basis. But the announcement has already changed conversations between US buyers and their overseas suppliers.
Generics fill about nine in ten US prescriptions, and FDA estimates that around 70% of them come from overseas. So even a threatened tariff deserves a plan. This piece sets out what is actually known, what is not, and the practical steps buyers and exporters can take now without overreacting.
It is a plain-language guide for sourcing and business development teams, not legal, tax or customs advice.
What is in place today
It helps to separate the two tracks.
- Patented medicines (in force). The Section 232 proclamation signed on 2 April 2026 put a tariff on patented medicines and their APIs. It applied first to a group of large companies from 31 July and to all importers from 29 September. Generic medicines, biosimilars and their ingredients are exempt. We covered the details in US pharma tariffs three weeks in.
- Generic medicines (announced, not in force). The July announcement says the current zero rate holds until the end of July 2028. It gives no detail on scope, on whether APIs are included, or on exemptions for companies that build US plants. The April proclamation separately asked the Commerce Department to report on generics, with a deadline in April 2027.
In short, nothing changes at the US border for generics today. The earliest date anything could change, on the current announcement, is August 2028.
Why the date matters more than the rate
A 100% or 200% tariff on a low-margin product would make most imports unviable, so the rate itself is not really the question. The question is whether US capacity can be ready in time, and the honest answer for most products is no. Industry leaders have said publicly that moving generic manufacturing to the US would take four to seven years. Building a sterile injectable plant, validating it and getting FDA approval for each product rarely takes less.
That gap leaves three realistic outcomes: the deadline moves; exemptions or company-by-company agreements are introduced, as happened with patented medicines; or some products leave the US market. The third outcome is the one buyers should prepare for, because old, low-margin generics are exactly the products already most prone to shortage. Our drug shortage radar shows how many of today's US shortages are older injectables with only one or two suppliers.
Five steps for US buyers
- Map where your products are made. For each generic you buy, know the finished-dose site and the API source. Under customs rules, origin usually follows the place where the product is substantially transformed, which is often the finished-dose site rather than the API plant. Do not assume; ask.
- Find your single points of failure. Products with one approved supplier, or several suppliers that all rely on the same API, carry the most risk under any tariff scenario.
- Review contract terms. Check who carries tariff costs under your Incoterms and supply agreements, and whether price-adjustment, force majeure or termination clauses would apply. New contracts running past mid-2028 should address this directly.
- Qualify a second source now. A second ANDA holder, a US or allied-country manufacturer, or a CDMO with spare capacity takes time to qualify. Starting in 2026 is not early.
- Watch two dates. The Commerce report due by April 2027 and any formal proclamation will show the real scope. Until then, avoid locking in decisions based on the headline alone.
Five steps for exporters supplying the US
- Talk to your customers early. Buyers are already asking. A clear, factual answer about your sites, your API sources and your plans builds trust and keeps you on approved-supplier lists.
- Look at US partnerships. Licensing an approved ANDA to a US manufacturer, using a US contract manufacturer for final steps where that changes origin, or a joint venture may protect a market that a tariff would close.
- Diversify your markets. Europe, the Gulf, Latin America and Africa are all buying more generics, and some are actively seeking new quality-assured suppliers. Our pharma tender calendar lists open public tenders.
- Keep compliance spotless. In a tighter market, an FDA warning letter or import alert would be even harder to recover from. Strong compliance is the best protection you have.
- Price carefully. Avoid long fixed-price commitments past mid-2028 without a tariff clause, but do not walk away from contracts based on an announcement alone.
The opportunity in the uncertainty
Uncertainty is uncomfortable, but it also opens doors. US buyers are looking for second sources and for suppliers in a wider range of countries. US-based and allied-country contract manufacturers are being asked about capacity. And products that some suppliers abandon will need someone to take them on. Our guide to this month's US shortages shows how compliant supply reaches patients when a product runs short.
How PharmaTradz can help
We connect US buyers with GMP-certified manufacturers and contract manufacturers in several regions, and we help exporters find licensing and manufacturing partners. If you need a second source, a US-market partner or a route into new markets, send us your requirement.
Frequently Asked Questions(FAQs)
Are generic medicines subject to US tariffs today?
No. Generics, biosimilars and their ingredients are exempt from the Section 232 tariff on patented medicines that applies to all importers from 29 September 2026.
What was announced about tariffs on generic drugs?
In July 2026 the US President announced on social media a 100% tariff on imported generics from August 2028, rising to 200% a year later. No formal order, product list or legal basis had been published by late October 2026.
Would the generic tariff cover APIs?
That has not been stated. The announcement gave no detail on scope. Watch for the Commerce Department's report on generics, due by April 2027, and any formal proclamation.
How is the origin of a generic medicine decided for US tariffs?
Origin generally follows the country where the product was substantially transformed, which is often where the finished dose is made rather than where the API comes from. Confirm the treatment of each product with a licensed customs broker.
What should US buyers of generics do now?
Map where each product and its API are made, identify single-source products, review tariff clauses in contracts that run past mid-2028, and start qualifying second sources.
Could a generic tariff cause more US drug shortages?
It could, if suppliers withdraw low-margin products before US capacity is ready. Older sterile injectables, which already make up many current shortages, are the most exposed.
